← LeaderboardsInvestigatorsiAttributed = a PI's even-split share of each grant — a $1M grant with 2 PIs counts $500K each.
Weill Medical College Of Cornell University
$145,124,859
Total funding
141
Grants
Funding over time
peak $29.5M · FY2008–25$50M$37.5M$25M$12.5M$0
'08
'09
'10
'11
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23
'24
'25
Funding mix
By agency
DOD$143,788,963 · 133
NASA$1,292,194 · 6
USDA$43,702 · 2
By mechanism
—$145,124,859 · 141
Investigators at Weill Medical College Of Cornell University
InvestigatorsiAttributed = a PI's even-split share of each grant — a $1M grant with 2 PIs counts $500K each.
Exposure= the full size of every grant they're on ($1M each).
Rising Stars
First grant in the last 5 yrs
Not enough data
Emerging Leaders
6–10 yrs in
Not enough data
All-Time
Most funded here, all years
Not enough data
Largest grants
ENHANCING EXPOSURE THERAPY FOR PTSD: VIRTUAL REALITY AND IMAGINAL EXPOSURE WITH A COGNITIVE ENHANCER$28,464,910
· FY2010 · Department of Defense
A PHASE 2 STUDY OF INHALED CO FOR THE TREATMENT OF ARDS$8,914,310
· FY2018 · Defense Health Agency
THERAPEUTIC TARGETING OF BREAST CANCER AND HOST IMMUNE RESPONSES AT INFLECTION POINTS IN THE DISEASE TRAJECTORY$6,552,437
· FY2021 · Defense Health Agency
A NON-INFERIORITY RANDOMIZED CONTROLLED TRIAL COMPARING INTERPERSONAL THERAPY TO EXPOSURE THERAPY FOR PTSD CONSEQUENT TO MST IN MALE & FEMALE PERSONN$4,077,741
· FY2018 · Defense Health Agency
CONVERTING HR+ BREAST CANCER INTO AN INDIVIDUALIZED VACCINE$4,051,497
· FY2019 · Defense Health Agency
RADIATION-INDUCED VACCINATION TO BREAST CANCER$3,194,818
· FY2011 · Department of Defense
HEATING COLD PROSTATE TUMORS WITH PSMA-TARGETED ALPHA THERAPY AND PEMBROLIZUMAB$3,119,537
· FY2020 · Defense Health Agency
THERAPEUTIC TARGETING OF THE TUMOR MICROENVIRONMENT IN TRIPLE-NEGATIVE BREAST CANCER PATIENTS AT HIGH RISK OF RELAPSE AND PRECLINICAL MODELS OF LUNG METASTASES$2,542,500
· FY2025 · Defense Health Agency
ORGANOTROPIC METASTATIC SECRETOMES AND EXOSOMES IN BREAST CANCER$2,139,265
· FY2013 · Department of Defense
REGULATION OF CARDIOGENESIS BY GATA TRANSCRIPTION FACTORS$2,014,593
· FY2017 · Department of the Army
BIOENERGETIC APPROACHES AND INFLAMMATION OF MPTP TOXICITY$1,975,561
· FY2008 · Department of the Army
TEMPORAL EVOLUTION OF N-MYC SIGNALING AND EARLY TARGETING OF THE NEUROENDOCRINE PHENOTYPE IN PROSTATE CANCER$1,780,847
· FY2017 · Defense Health Agency
CIRCULATING ANTIBODY REPERTOIRE AND BLOOD-BRAIN-BARRIER IMPAIRMENT TO EXPLAIN NEUROPSYCHIATRIC SYMPTOMS OF "INVISIBLE" BRAIN INJURY$1,751,468
· FY2025 · Defense Health Agency
TARGETED THERAPIES$1,730,727
· FY2022 · Defense Health Agency
CONVERTING HR+ BREAST CANCER INTO AN INDIVIDUALIZED VACCINE$1,694,998
· FY2019 · Defense Health Agency
THERANOSTIC TROP-2-DIRECTED PRETARGETED RADIOIMMUNOTHERAPY FOR METASTATIC$1,685,582
· FY2025 · Defense Health Agency
INVESTIGATION OF UBR5 AND ITS SIGNALING AS A NOVEL 3. TARGET FOR BREAST CANCER THERAPY$1,589,407
· FY2021 · Defense Health Agency
ENHANCING BREAST CANCER THERAPY BY INHIBITING THE ADENOSINE RECEPTOR AND OXYGEN CONSUMPTION$1,585,159
· FY2021 · Defense Health Agency
EARLY DETECTION BLOOD TEST FOR UNIVERSAL BREAST CANCER SCREENING TO IMPROVE EARLY DIAGNOSIS FOR WOMEN OF ALL SOCIAL AND ETHNIC BACKGROUNDS$1,419,023
· FY2025 · Defense Health Agency
RESTORATION OF CLEAR CELL RENAL CELL CARCINOMA TUMORIGENICITY BY CELL REPROGRAMMING$1,356,000
· FY2024 · Defense Health Agency